Comparison of clinical and MRI features of brain metastases between ALK+ and ALK‐ NSCLC

Documenti analoghi

• Survival Trends and Prognostic Modeling in ALK ‐Positive Anaplastic Large Cell Lymphoma: A Population‐Based Study in the Brentuximab Vedotin Era
  di: Qiuyu Zhang, et al.
  Pubblicazione: (2026)
• The association of genomic alterations with PD‐L1 expression in Chinese patients with EGFR/ALK wild‐type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy
  di: Fangfang Liu, et al.
  Pubblicazione: (2024)
• PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence
  di: Litang Huang, et al.
  Pubblicazione: (2024)
• Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
  di: Qiran Wei, et al.
  Pubblicazione: (2024)
• Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC
  di: Yuxiang Sun, et al.
  Pubblicazione: (2026)